Mesoblast announced it is seeking accelerated approval in the US via a BLA filing with the FDA.
1 report, 0 independent
Updated Jul 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Mesoblast announced it is seeking accelerated approval in the US via a BLA filing with the FDA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Mesoblast is seeking FDA review of the BLA for its product rexlemestrocel-L.Sub-event
- Mesoblast is pursuing accelerated approval in the US through a BLA filing with the FDA.
Keep exploring
The entities involved
Related events
- Immuron anticipates receiving FDA approval for its IND submission.
- The FDA and Intellia Therapeutics are preparing a regulatory filing for product approval.
- FDA granted Priority Review for the BLA submission of the SkinTE product.
- The FDA is currently reviewing new drug applications for market entry.
- FDA approval enables commercial opportunity involving CBRE Group.
Coverage
Newest first; wire copies grouped- Unknown outlet